The company earlier this month lowered its IPO projection from $15 million to $10 million, anticipating fewer proceeds. Semler ultimately sold about 1.4 million shares of common stock at $7 apiece.
SMLR shares have lost 0.6% since their launch and closed at $6.95 on Friday.
Semler develops tools to assess medical risk in patients. The company’s mission is to "develop, manufacture and market patented products that identify the risk profile of medical patients to allow healthcare providers to capture full reimbursement potential for their services," according to a press release.
The company’s 1st product is the FDA-cleared FloCheck device for measuring arterial blood flow in the extremities.